Chetan Lathia

Chetan Lathia is a seasoned professional in regulatory affairs, clinical pharmacology, and nonclinical development with extensive experience in the pharmaceutical industry. Currently serving as SVP at Radionetics Oncology, Chetan leads regulatory strategy and engages with FDA and global agencies to facilitate drug development. Prior to this role, Chetan held senior positions at BioXcel Therapeutics as Senior VP, Intarcia Therapeutics as Vice President, and Alexion Pharmaceuticals as Executive Director, where responsibilities included managing clinical pharmacology, regulatory affairs, and pharmacometrics. Chetan's career began at Bayer Pharmaceuticals and Parke-Davis, contributing to oncology and cardiovascular research, and has a strong educational background with a B.S. in Pharmacy and a Ph.D. in Clinical Pharmacology/Pharmacokinetics from reputable institutions.